Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California.  In addition, the company announced that it has commenced enrollment of patients with type 2 diabetes in its Phase 2b clinical trial of LX4211.

Data from the mechanistic study demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the poster from the ADA meeting, please visit www.lexpharma.com.

The Phase 2b trial is a randomized, double-blind, placebo controlled study of LX4211 in approximately 285 adult patients (18-75 years) with type 2 diabetes who are not adequately controlled on metformin monotherapy.  Patients will be administered LX4211 in combination with standard metformin therapy over 12 weeks.  Doses will include 75 mg once daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily or placebo.  The primary endpoint of the study is the change from baseline in HbA1c at Week 12.  Secondary endpoints will include percentage of patients achieving HbA1c < 7%, and changes in fasting plasma glucose, 3-hour glucose tolerance test, weight, blood pressure, and triglycerides.  The study will be conducted at ap
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... , , ... personal injury attorney John David Hart has filed 29 lawsuits against ... Medtronic USA, Inc. and Medtronic Puerto Rico Operations Co., in connection ... fractures which could result in serious injury or death. , ...
... , , , ... today announced its first device, the ZOOM-100DC brain electrical activity ... U.S. Food and Drug Administration under section 510(k) of the ... electroencephalogram (EEG) device capable of recording and displaying EEG waveforms ...
... SCOTTSDALE, Ariz., Aug. 11 ... of interoperable workflow solutions that advance the quality and safety of ... e fe r ral , its portal-based ... a streamlined, patient-centric and highly accountable process for tracking referrals. ...
... , , HOUSTON, Aug. 11 ... on workers, compensation, has announced its recent network certification in the ... few to achieve this certification, which covers all 159 counties in ... to leading workers, compensation providers for third party administrators, managed care ...
... , , HERMOSA BEACH, Calif., ... Cancer (PADRES), a non-profit organization committed to improving the quality of life for ... Volleyball match as part of the 2009 AVP CROCS SLAM BUD ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090811/LA59829 ) , , ...
... National Non-profit Provides No ... ... know that cataracts are the leading cause of vision loss among adults 55 and ... cataract development. , , , , ,Moreover, a recent study out of the University of ...
Cached Medicine News:Health News:Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches 2Health News:BrainScope(TM) Receives FDA Clearance for Portable EEG Device 2Health News:BrainScope(TM) Receives FDA Clearance for Portable EEG Device 3Health News:Carefx's New Referral Management Solution Increases Hospital Referral Volume, Enhances Collaboration Among Specialists, PCPs and Patients 2Health News:Carefx's New Referral Management Solution Increases Hospital Referral Volume, Enhances Collaboration Among Specialists, PCPs and Patients 3Health News:Carefx's New Referral Management Solution Increases Hospital Referral Volume, Enhances Collaboration Among Specialists, PCPs and Patients 4Health News:Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 2Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 2Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 3Health News:EyeCare America Works to Prevent Blindness Caused by Cataracts 2Health News:EyeCare America Works to Prevent Blindness Caused by Cataracts 3
... HIBICLENS bonds with ... a protective, germ-killing field. ... fast acting antimicrobial effect, ... irritation potential promotes compliance ...
... solution, allows the user to prep one ... in less than 2-minutes. It also utilizes ... surgical scrubbing and healthcare personnel handwashing. ACTIPREP ... provide a tacky surface for drapes to ...
... This multi-purpose topical gel contains 10% ... broad-spectrum germicidal action. As a pre-operative prep, ... pooling of prepping solutions under the patient, ... The Gel is also approved as a ...
... Scrub is a gentle and effective surgical ... dryness. Povidone Iodine is known to kill ... bacteria, fungi, viruses, protozoa and yeasts. It ... step in patient pre-operative prepping, as well ...
Medicine Products: